Title : Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.

Pub. Date : 2019 Jan 1

PMID : 30422156






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The main eligibility criterion was disease progression after bevacizumab plus fluorouracil with irinotecan or oxaliplatin in patients with wild-type KRAS exon 2 metastatic colorectal cancer. Oxaliplatin KRAS proto-oncogene, GTPase Homo sapiens